Online inquiry

IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13072MR)

This product GTTS-WQ13072MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MADCAM1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_130760.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8174
UniProt ID Q13477
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13072MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3089MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ5226MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ10403MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ15771MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ1700MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ12072MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ6926MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ6821MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW